Which hedge funds own AKTS? AKTIS ONCOLOGY INC, Q2 2026 13F holders
24 tracked hedge funds disclosed a position in AKTS (AKTIS ONCOLOGY INC) in their Q2 2026 13F filings, worth $521.5m in total. The largest holder by portfolio weight is MPM Bioimpact LLC at 9.5% of its book. 9 opened a new position this quarter: Sofinnova Investments, Inc., Polen Capital, Renaissance Technologies LLC, Tudor Investment Corp ET AL. 3 exited: Laurion Capital Management LP, Zimmer Partners, LP, D. E. Shaw & Co., Inc..
- 24
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 9
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 3
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $10.6m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $2.4m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $521m
- Combined value Sum of the holders' reported positions in the security.
- 1.9%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Laurion Capital Management LP | 0.2% | $1.8m |
| Zimmer Partners, LP | 0.01% | $268k |
| D. E. Shaw & Co., Inc. | 0.0% | $305k |
Ownership over time
Who discovered AKTS first? Beta
| MPM Bioimpact LLC high conviction | Q1 2026 | +5.4 pts |
| EcoR1 Capital, LLC high conviction | Q2 2026 | +3.0 pts |
| Octagon Capital Advisors LP | Q1 2026 | +1.5 pts |
| Avidity Partners Management LP | Q1 2026 | +1.4 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.